Different expression patterns of p27KIP1 and p57KIP2 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes

Journal of Cutaneous Pathology

Volumn 36, Issue 2, 2009, Pages 197-205

  Curry, Jonathan L ^a   Richards, Hunter W ^a   Huttenbach, Yve T ^a   Medrano, Estela E ^a   Reed, Jon A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C;

ANIMAL CELL; ARTICLE; BENIGN TUMOR; CELL CULTURE; CELL GROWTH; CELL NUCLEUS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; MOUSE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P57; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOCYTES; MELANOMA; SKIN NEOPLASMS;

EID: 58649110849     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2008.00998.x     Document Type: Article

References (34)

1. Mainprize TG, Taylor MD, Rutka JT, Dirks PB. Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. J Neurooncol 2001 51 : 205.
2. Li W, Sanki A, Karim RZ et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006 38 : 287.
3. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995 9 : 639.
4. Bhuiyan ZA, Yatsuki H, Sasaguri T et al. Functional analysis of the p57KIP2 gene mutation in Beckwith-Wiedemann syndrome. Hum Genet 1999 104 : 205.
5. Michaloglou C, Vredeveld LC, Soengas MS et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005 436 : 720.
6. Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat Genet 2003 33 : 19.
7. Gray-Schopfer VC, Cheong SC, Chong H et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006 95 : 496.
8. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev 1997 11 : 663.
9. Bales ES, Dietrich C, Bandyopadhyay D et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999 113 : 1039.
10. Trotter MJ, Tang L, Tron VA. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 1997 24 : 265.
11. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994 8 : 1750.
12. Tchernev G, Orfanos CE. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J Cutan Pathol 2007 34 : 247.
13. Li JQ, Wu F, Usuki H et al. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 2003 23 : 1537.
14. Fan GK, Chen J, Ping F, Geng Y. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral Oncol 2006 42 : 147.
15. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 2002 22 : 3191.
16. Nakai S, Masaki T, Shiratori Y et al. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol 2002 20 : 769.
17. Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J (Engl) 2003 116 : 20.
18. Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A 1998 95 : 1392.
19. Nijjar T, Wigington D, Garbe JC, Waha A, Stampfer MR, Yaswen P. p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Res 1999 59 : 5112.
20. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004 18 : 862.
21. Sicinski P, Zacharek S, Kim C. Duality of p27Kip1 function in tumorigenesis. Genes Dev 2007 21 : 1703.
22. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003 13 : 65.
23. Zhang P, Wong C, Liu D, Finegold M, Harper JW, EHedge SJ. p21(CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev 1999 13 : 213.
24. Medrano EE, Nordlund JJ. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990 95 : 441.
25. Bandyopadhyay D, Curry JL, Lin Q et al. Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi. Aging Cell 2007 4 : 577.
26. Kornberg R, Ackerman AB. Pseudomelanoma: recurrent melanocytic nevus following partial surgical removal. Arch Dermatol 1975 111 : 1588.
27. Hoang MP, Prieto VG, Burchette JL, Shea CR. Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol 2001 28 : 400.
28. Woenckhaus C, Maile S, Uffmann S et al. Expression of Skp2 and p27KIP1 in naevi and malignant melanoma of the skin and its relation to clinical outcome. Histol Histopathol 2005 20 : 501.
29. Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res 2002 15 : 242.
30. Reed JA, Loganzo F, Jr., Shea CR et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995 55 : 2713.
31. Ghiorzo P, Pastorino L, Bonelli L et al. INK4/ARF germline alterations in pancreatic cancer patients. Ann Oncol 2004 15 : 70.
32. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000 6 : 1845.
33. Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 2007 14 : 1497.
34. Reed JA, Lin Q, Chen D, Mian IS, Medrano EE. SKI pathways inducing progression of human melanoma. Cancer Metastasis Rev 2005 24 : 265.